Found 345 Results
Page 1 of 35

Onxeo reports its financial results for the first half of 2020 and provides an update on its activities

The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]


Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020

Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]


HealthTech Innovation Days – France Biotech

October 5-6, 2020 in Paris, France (virtual conference) This event includes conferences and meetings between innovative European companies in the […]


Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]



Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer

DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]



Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility

Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]


H.C. Wainwright 22nd Annual Global Investment Conference

September 14-16, 2020 (virtual conference) Onxeo’s management team will present the Company on September 15 at 1:00 pm EDT (19:00 […]


Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux

July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]



Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]



New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020

Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells   […]



Page 1 of 35

No more results